Rigel Pharmaceuticals, Inc. reported significant financial growth in its quarterly filing for the period ending September 30, 2025. The company achieved total revenues of $69.5 million for the third quarter, a 25.5% increase from $55.3 million in the same period last year. For the nine months ending September 30, 2025, total revenues reached $224.5 million, up from $121.7 million in 2024. This growth was primarily driven by a substantial increase in product sales, which rose to $64.1 million in the third quarter, compared to $38.9 million in the prior year, and $166.6 million for the nine-month period, up from $98.4 million.
The company's net income for the third quarter was $27.9 million, or $1.55 per share, compared to $12.4 million, or $0.71 per share, in the same quarter of 2024. For the nine-month period, net income surged to $99.0 million, significantly higher than the $3.1 million reported in the previous year. Rigel's financial performance reflects a strategic focus on its commercial products, particularly TAVALISSE, REZLIDHIA, and GAVRETO, which have seen increased adoption and sales.
Operationally, Rigel has made notable advancements, including the successful commercialization of GAVRETO, which began in June 2024. The product generated $31.9 million in sales for the nine months ended September 30, 2025, compared to $9.0 million in the same period of 2024. The company also reported a significant increase in customer engagement, with McKesson Corporation and Cencora, Inc. being key contributors to its revenue, accounting for 48% and 23% of product sales, respectively.
Rigel's balance sheet as of September 30, 2025, showed total assets of $242.5 million, up from $164.0 million at the end of 2024. The company had cash and cash equivalents of $48.5 million and short-term investments of $88.6 million. Rigel's strategic collaborations, including those with MD Anderson Cancer Center and Eli Lilly, continue to enhance its research and development capabilities, although the recent notice from Lilly regarding the termination of the CNS disease program may impact future revenue streams.
Looking ahead, Rigel anticipates that its existing cash and investments will be sufficient to fund operations for at least the next 12 months. The company remains focused on expanding its product portfolio and enhancing its market presence, while navigating the complexities of regulatory approvals and market competition. Rigel's ongoing clinical trials and collaborations are expected to play a crucial role in its future growth and success in the biotechnology sector.
About RIGEL PHARMACEUTICALS INC
Rigel Pharmaceuticals is a biotech company focused on developing therapies for hematologic disorders and cancer. Its core products include FDA-approved treatments for immune thrombocytopenia, AML with IDH1 mutations, and RET fusion-positive cancers. The company leverages strategic collaborations, licensing, and a commercial infrastructure to develop, manufacture, and market targeted therapies globally, emphasizing innovation in oncology and hematology.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.